Rare Disease CDMOs in United States
10 published
10 published CDMOs match Rare Disease in United States.
Locations in this set include United States, China, Brazil, France, India, and Singapore.
Capabilities that show up most often in this set: CMC Analytical Development, Process Development, CMC Regulatory Submission Support, Quality Control Testing, and Technology Transfer.
Matching companies
AldevronAldevron is a CDMO specializing in mRNA manufacturing with LNP encapsulation and fill/finish, viral vector production, plasmid DNA, and gene therapy solutions from discovery through commercialization.
Andelyn BiosciencesCDMO specializing in plasmid DNA and AAV viral vector manufacturing for cell and gene therapy, with digital-first platform emphasizing data integrity and collaboration.
AskBioAskBio is a clinical-stage gene therapy company developing AAV gene therapies for genetic and rare disorders, with a focus on advancing genetic technology and lowering production costs to increase patient access.
Cytovance BiologicsU.S.-based CDMO offering end-to-end biomanufacturing services for antibodies, recombinant proteins, vaccines, and other biologics modalities, with dedicated microbial and mammalian facilities and in-house cell line development capabilities.
ElevateBioAdvanced therapies CDMO providing discovery, process development, manufacturing, and regulatory support for cell therapies, viral vectors, mRNA, and gene editing programs from preclinical through commercial scale.
Forge BiologicsDedicated AAV gene therapy CDMO with a 200,000+ sq. ft. cGMP facility featuring 20 suites and bioreactors up to 5,000L, supporting 60+ clients across 35+ indications with high-yield manufacturing and seamless regulatory compliance.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Stason Industrial CorporationUS-based CDMO offering contract packaging, analytical testing, and manufacturing services for clinical trial and commercial pharmaceutical production, with specialized high-containment capabilities for potent compounds.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
Unither PharmaceuticalsGlobal CDMO specializing in sterile and non-sterile liquid manufacturing, including Blow-Fill-Seal (BFS) single-dose technology with over 5 billion annual capacity, plus formulation development, analytical services, and ophthalmic expertise across six production sites.
Markdown mirror: /indications/rare-disease/us.md